Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is intended for the treatment of acute lymphoblastic leukaemia and lymphoblastic lymphoma in patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase
Through a machine-learning model, many carcinomas of unknown primary can be classified into meaningful subgroups with the potential to aid clinical decision making
Findings from the GO42144 study
Findings from the COLUMBUS part 2 study
Conversion to regular approval is based on data from additionally included patients and additional follow-up in the ARROW study
It is indicated for the treatment of adult patients with newly diagnosed AML who are ineligible for standard induction chemotherapy
Findings from the Atezo-Brain study
Findings from the MEDITREME study
Findings from the registrational phase II MagnetisMM-3 study
Evidence for efficacy is based on the results from the MAGNITUDE study
New indication concerns the combination first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
Findings from the INHERIT study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
